226 related articles for article (PubMed ID: 24726032)
1. A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective anticoagulation length with low molecular weight heparin in the treatment of cancer associated thrombosis (ALICAT): study protocol for a mixed-methods study.
Smith JD; Baillie J; Baglin T; Griffiths GO; Casbard A; Cohen D; Fitzmaurice DA; Hood K; Rose P; Cohen AT; Johnson M; Maraveyas A; Bell J; Toone H; Nelson A; Noble SI
Trials; 2014 Apr; 15():122. PubMed ID: 24726032
[TBL] [Abstract][Full Text] [Related]
2. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT).
Noble SI; Nelson A; Fitzmaurice D; Bekkers MJ; Baillie J; Sivell S; Canham J; Smith JD; Casbard A; Cohen A; Cohen D; Evans J; Fletcher K; Johnson M; Maraveyas A; Prout H; Hood K
Health Technol Assess; 2015 Oct; 19(83):vii-xxiii, 1-93. PubMed ID: 26490434
[TBL] [Abstract][Full Text] [Related]
3. Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis.
Connell NT; Abel GA; Connors JM
Thromb Res; 2017 Feb; 150():53-58. PubMed ID: 28039844
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial.
Fowler RA; Mittmann N; Geerts WH; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
Trials; 2014 Dec; 15():502. PubMed ID: 25528663
[TBL] [Abstract][Full Text] [Related]
5. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective.
Hull RD; Raskob GE; Rosenbloom D; Pineo GF; Lerner RG; Gafni A; Trowbridge AA; Elliott CG; Green D; Feinglass J
Arch Intern Med; 1997 Feb; 157(3):289-94. PubMed ID: 9040295
[TBL] [Abstract][Full Text] [Related]
6. Profile of low molecular weight tinzaparin sodium for anticoagulation during hemodialysis.
Al-Saran KA; Sabry A; Taha M; Ghafour MA; Al Fawzan F
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):43-9. PubMed ID: 20061691
[TBL] [Abstract][Full Text] [Related]
7. Role of current and emerging antithrombotics in thrombosis and cancer.
Mousa SA
Drugs Today (Barc); 2006 May; 42(5):331-50. PubMed ID: 16801996
[TBL] [Abstract][Full Text] [Related]
8. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N
Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635
[TBL] [Abstract][Full Text] [Related]
9. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis.
Marchetti M; Pistorio A; Barone M; Serafini S; Barosi G
Am J Med; 2001 Aug; 111(2):130-9. PubMed ID: 11498067
[TBL] [Abstract][Full Text] [Related]
10. Low-molecular-weight heparin for initial treatment of venous thromboembolism.
Brewer D
Am Fam Physician; 2005 Jul; 72(1):75-6. PubMed ID: 16035683
[No Abstract] [Full Text] [Related]
11. Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation.
Pandor A; Horner D; Davis S; Goodacre S; Stevens JW; Clowes M; Hunt BJ; Nokes T; Keenan J; de Wit K
Health Technol Assess; 2019 Dec; 23(63):1-190. PubMed ID: 31851608
[TBL] [Abstract][Full Text] [Related]
12. Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.
Junqueira DR; Zorzela LM; Perini E
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007557. PubMed ID: 28431186
[TBL] [Abstract][Full Text] [Related]
13. Development of the IRIS-AR strategy: an intervention to improve rates of accrual and retention for the VTE-PRO randomized controlled trial.
Fahim C; Hylton D; Simunovic M; Agzarian J; Finley C; Hanna WC; Shargall Y
Trials; 2019 Jul; 20(1):447. PubMed ID: 31324209
[TBL] [Abstract][Full Text] [Related]
14. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH; Muntz J
Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
[TBL] [Abstract][Full Text] [Related]
16. Cov-hep study: heparin in standard anticoagulation based on citrate for continuous veno-venous hemodialysis in patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Lins PRG; de Albuquerque CCC; Assis CF; Rodrigues BCD; E Siqueira Campos BP; de Oliveira Valle E; Cabrera CPS; de Oliveira Gois J; Segura GC; Strufaldi FL; Mainardes LC; Ribeiro RG; Via Reque Cortes DDP; Lutf LG; de Oliveira MFA; Sales GTM; Smolentzov I; Reichert BV; Andrade L; Seabra VF; Rodrigues CE
Trials; 2020 Nov; 21(1):920. PubMed ID: 33176886
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update.
Franco-Moreno A; Cabezón-Gutiérrez L; Palka-Kotlowsa M; Villamayor-Delgado M; García-Navarro M
J Thromb Thrombolysis; 2019 Apr; 47(3):409-419. PubMed ID: 30467760
[TBL] [Abstract][Full Text] [Related]
18. Controversies in the management of cancer-associated thrombosis.
Carrier M; Prandoni P
Expert Rev Hematol; 2017 Jan; 10(1):15-22. PubMed ID: 27869512
[TBL] [Abstract][Full Text] [Related]
19. Parenteral anticoagulation in ambulatory patients with cancer.
Akl EA; Kahale LA; Hakoum MB; Matar CF; Sperati F; Barba M; Yosuico VED; Terrenato I; Synnot A; Schünemann H
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD006652. PubMed ID: 28892556
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
